Dyne Therapeutics, Inc. Common Stock DYN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:56:55.963Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:02.513446961Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T00:56:55.588099+00:00
Dyne Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 13.29 | 335.9% | 33.8% | |||
| 25Δ | 15.47 | 174.3% | 18.6% | |||
| 30Δ | 16.21 | 157.0% | 15.1% | |||
| 35Δ | 23.98 | 298.3% | 42.0% | 16.95 | 139.8% | 11.6% |
| 40Δ | ||||||
| 45Δ | 18.17 | 204.7% | 12.2% | |||
| 50Δ | 18.71 | 182.2% | 9.6% | |||
| 55Δ | 17.82 | 54.7% | 3.2% | 19.14 | 162.1% | 7.6% |
| 60Δ | 17.53 | 57.4% | 2.8% | 19.43 | 144.7% | 6.0% |
| 65Δ | 17.24 | 60.1% | 2.4% | 19.73 | 127.4% | 4.4% |
| 70Δ | 16.95 | 62.8% | 2.1% | 20.04 | 111.1% | 3.0% |
| 75Δ | 16.67 | 65.5% | 1.7% | 20.52 | 106.6% | 2.3% |
| 80Δ | 16.38 | 68.2% | 1.4% | 21.00 | 102.0% | 1.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.29
- IV
- 335.9%
- B/E move
- 33.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.47
- IV
- 174.3%
- B/E move
- 18.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.21
- IV
- 157.0%
- B/E move
- 15.1%
35Δ
- Pseudo strike
- 23.98
- IV
- 298.3%
- B/E move
- 42.0%
- Pseudo strike
- 16.95
- IV
- 139.8%
- B/E move
- 11.6%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.17
- IV
- 204.7%
- B/E move
- 12.2%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.71
- IV
- 182.2%
- B/E move
- 9.6%
55Δ
- Pseudo strike
- 17.82
- IV
- 54.7%
- B/E move
- 3.2%
- Pseudo strike
- 19.14
- IV
- 162.1%
- B/E move
- 7.6%
60Δ
- Pseudo strike
- 17.53
- IV
- 57.4%
- B/E move
- 2.8%
- Pseudo strike
- 19.43
- IV
- 144.7%
- B/E move
- 6.0%
65Δ
- Pseudo strike
- 17.24
- IV
- 60.1%
- B/E move
- 2.4%
- Pseudo strike
- 19.73
- IV
- 127.4%
- B/E move
- 4.4%
70Δ
- Pseudo strike
- 16.95
- IV
- 62.8%
- B/E move
- 2.1%
- Pseudo strike
- 20.04
- IV
- 111.1%
- B/E move
- 3.0%
75Δ
- Pseudo strike
- 16.67
- IV
- 65.5%
- B/E move
- 1.7%
- Pseudo strike
- 20.52
- IV
- 106.6%
- B/E move
- 2.3%
80Δ
- Pseudo strike
- 16.38
- IV
- 68.2%
- B/E move
- 1.4%
- Pseudo strike
- 21.00
- IV
- 102.0%
- B/E move
- 1.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 94.40% | |
| 91.98% | |
| 88.71% | |
| 90.24% | |
| 90.54% | |
| 87.60% | |
| 95.95% | |
| 99.41% | |
| 89.81% | |
| 118.14% |
Biotechnology
EDIT
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is…
More →ELDN
Description unavailable
More →ELTX
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002,…
More →ELVN
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its…
More →ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to…
More →ENTA
Description unavailable
More →